{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-14T16:19:39.788706+00:00","company":{"ticker":"INM","cik":1728328,"company_name":"InMed Pharmaceuticals Inc."},"pagination":{"limit":100,"returned":34,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Armistice Capital Master Fund Ltd.","detail":"equity_purchase","count":1,"first_seen":"2026-05-19T10:03:08+00:00","last_seen":"2026-05-19T10:03:08+00:00","evidence_fact_ids":[97033]},{"display_name":"H.C. Wainwright & Co., LLC","detail":"underwriting","count":1,"first_seen":"2022-11-22T23:59:59+00:00","last_seen":"2022-11-22T23:59:59+00:00","evidence_fact_ids":[194806]},{"display_name":"Mentari Therapeutics, Inc.","detail":"merger","count":1,"first_seen":"2026-05-19T14:32:30+00:00","last_seen":"2026-05-19T14:32:30+00:00","evidence_fact_ids":[96603]},{"display_name":"Sabby Volatility Warrant Master Fund, Ltd.","detail":"equity_purchase","count":1,"first_seen":"2026-04-27T23:59:59+00:00","last_seen":"2026-04-27T23:59:59+00:00","evidence_fact_ids":[22867]},{"display_name":"affiliates of H.C. Wainwright & Co., LLC","detail":"equity_purchase","count":1,"first_seen":"2026-04-27T23:59:59+00:00","last_seen":"2026-04-27T23:59:59+00:00","evidence_fact_ids":[22868]}]},"facts":[{"fact_type":"material_agreement","fact_key":"c9bca14692752c67f398aa575b5aab0a9ba123c8","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-05-19T14:32:30+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger and Reorganization","agreement_type":"merger","counterparty":"Mentari Therapeutics, Inc.","effective_date":"2026-05-19","item_codes_triggered":["1.01"],"value_text":"equity value of $125,000,000"},"claim":"InMed Pharmaceuticals Inc. entered into Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, Inc. valued at equity value of $125,000,000 (effective 2026-05-19).","evidence_excerpt":"ub, the “ Merger Subs ”), and Mentari Therapeutics, Inc., a Delaware corporation (“ Mentari ”), entered\ninto an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”), pursuant to which, among other matters","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-058795","anchor_url":"https://secwatch.observer/filing/0001213900-26-058795#claim-c9bca14692752c67f398aa575b5aab0a9ba123c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026058795/0001213900-26-058795-index.htm"},{"fact_type":"material_agreement","fact_key":"cff8f74494f8b4eea786a178fe2f6b95dc2e462f","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-05-19T10:03:08+00:00","payload":{"action":"amendment","agreement_name":"Armistice Preferred Investment Option Amending Agreement","agreement_type":"equity_purchase","counterparty":"Armistice Capital Master Fund Ltd.","effective_date":"2026-05-18","item_codes_triggered":["1.01"],"value_text":null},"claim":"InMed Pharmaceuticals Inc. amended Armistice Preferred Investment Option Amending Agreement with Armistice Capital Master Fund Ltd. (effective 2026-05-18).","evidence_excerpt":"On May 18, 2026, the Company entered into a preferred investment option amending agreement (the \"Armistice Preferred Investment Option Amending Agreement\") with Armistice to amend the Armistice Exercise Price contained in the Armistice Preferred Investment Options from $16.60 to $0.80.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001062993-26-002787","anchor_url":"https://secwatch.observer/filing/0001062993-26-002787#claim-cff8f74494f8b4eea786a178fe2f6b95dc2e462f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326002787/0001062993-26-002787-index.htm"},{"fact_type":"equity_issuance","fact_key":"0b51078f8cbf76bda895e08cd8111a418e706d8e","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-04-27T23:59:59+00:00","payload":{"action":"rights_modification","consideration_text":"amended the Wainwright Exercise Prices contained in each Wainwright Preferred Investment Option to $0.80","effective_date":"2026-04-24","item_codes_triggered":["3.03"],"purchaser":"affiliates of H.C. Wainwright & Co., LLC","security_type":"warrant","shares_text":"up to 153,236 common shares (on a post-consolidation basis)"},"claim":"InMed Pharmaceuticals Inc. issued up to 153,236 common shares (on a post-consolidation basis) of warrant to affiliates of H.C. Wainwright & Co., LLC for amended the Wainwright Exercise Prices contained in each Wainwright Preferred Investment Option to $0.80.","evidence_excerpt":"On April 24, 2026, the Company entered into Preferred Investment Option Amending Agreements (the “Wainwright Preferred Investment Option Amending Agreements”) with each Wainwright Party to amend the Wainwright Exercise Prices contained in each Wainwright Preferred Investment Option to $0.80.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-048064","anchor_url":"https://secwatch.observer/filing/0001213900-26-048064#claim-0b51078f8cbf76bda895e08cd8111a418e706d8e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026048064/0001213900-26-048064-index.htm"},{"fact_type":"equity_issuance","fact_key":"4f429faf7469d0c434e69c2b982c558140792ad3","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-04-27T23:59:59+00:00","payload":{"action":"rights_modification","consideration_text":"amended the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80","effective_date":"2026-04-21","item_codes_triggered":["3.03"],"purchaser":"Sabby Volatility Warrant Master Fund, Ltd.","security_type":"warrant","shares_text":"up to 2,151,478 common shares"},"claim":"InMed Pharmaceuticals Inc. issued up to 2,151,478 common shares of warrant to Sabby Volatility Warrant Master Fund, Ltd. for amended the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80.","evidence_excerpt":"On April 21, 2026, the Company entered into a Preferred Investment Option Amending Agreement (the “Sabby Preferred Investment Option Amending Agreement”) with Sabby to amend the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-048064","anchor_url":"https://secwatch.observer/filing/0001213900-26-048064#claim-4f429faf7469d0c434e69c2b982c558140792ad3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026048064/0001213900-26-048064-index.htm"},{"fact_type":"material_agreement","fact_key":"ad3cf0b0f6eccc4a4567682e696c5602c38ad8f8","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-04-27T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Wainwright Preferred Investment Option Amending Agreements","agreement_type":"equity_purchase","counterparty":"affiliates of H.C. Wainwright & Co., LLC","effective_date":"2026-04-24","item_codes_triggered":["1.01"],"value_text":null},"claim":"InMed Pharmaceuticals Inc. amended Wainwright Preferred Investment Option Amending Agreements with affiliates of H.C. Wainwright & Co., LLC (effective 2026-04-24).","evidence_excerpt":"On April 24, 2026, the Company entered into Preferred Investment Option Amending Agreements (the “Wainwright Preferred Investment Option Amending Agreements”) with each Wainwright Party to amend the Wainwright Exercise Prices contained in each Wainwright Preferred Investment Option to $0.80.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-048064","anchor_url":"https://secwatch.observer/filing/0001213900-26-048064#claim-ad3cf0b0f6eccc4a4567682e696c5602c38ad8f8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026048064/0001213900-26-048064-index.htm"},{"fact_type":"material_agreement","fact_key":"5cab304f29c07e99219417680d1e621ca5c3d0d5","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-04-27T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Sabby Preferred Investment Option Amending Agreement","agreement_type":"equity_purchase","counterparty":"Sabby Volatility Warrant Master Fund, Ltd.","effective_date":"2026-04-21","item_codes_triggered":["1.01"],"value_text":null},"claim":"InMed Pharmaceuticals Inc. amended Sabby Preferred Investment Option Amending Agreement with Sabby Volatility Warrant Master Fund, Ltd. (effective 2026-04-21).","evidence_excerpt":"On April 21, 2026, the Company entered into a Preferred Investment Option Amending Agreement (the “Sabby Preferred Investment Option Amending Agreement”) with Sabby to amend the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-048064","anchor_url":"https://secwatch.observer/filing/0001213900-26-048064#claim-5cab304f29c07e99219417680d1e621ca5c3d0d5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026048064/0001213900-26-048064-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"6680686ee12f6bcf82efda56053d979aa4e7e9b2","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-03-30T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2026-09-23","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$1.00 per share","notice_date":"2026-03-27","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2)","reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"InMed Pharmaceuticals Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"March 27, 2026, InMed Pharmaceuticals Inc. (the \"Company\") received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\"Nasdaq\") notifying it that the closing bid price of the Company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) during the February 11, 2026 to March 26, 2026 period. In accordance with applicable Nasdaq procedures, the Company has a period of 180 calendar days following the receipt of t","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001062993-26-001697","anchor_url":"https://secwatch.observer/filing/0001062993-26-001697#claim-6680686ee12f6bcf82efda56053d979aa4e7e9b2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326001697/0001062993-26-001697-index.htm"},{"fact_type":"restructuring_charge","fact_key":"e6ba4a45c949c2489b920e25c5e7d22f9d7dd578","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-03-06T23:59:59+00:00","payload":{"affected_area":"BayMedica LLC commercial operations business segment","charge_text":"severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000","effective_date":"2026-03-04","event_type":"restructuring","headcount_text":null,"item_codes_triggered":["2.05"]},"claim":"InMed Pharmaceuticals Inc. announced a restructuring with charges of severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000 affecting BayMedica LLC commercial operations business segment.","evidence_excerpt":"In connection with the wind down of commercial operations, BayMedica is expected to incur severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000 through the end of the fiscal year.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-024752","anchor_url":"https://secwatch.observer/filing/0001213900-26-024752#claim-e6ba4a45c949c2489b920e25c5e7d22f9d7dd578","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026024752/0001213900-26-024752-index.htm"},{"fact_type":"executive_change","fact_key":"24fb6427fb","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2025-02-14T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-10","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Janet Grove resigned as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"On February 10, 2025, the Board elected to accept Ms. Grove’s resignation from the Board, including from her positions as a member of the Compensation Committee and Chair of the Nominating & Governance Committee.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-014154","anchor_url":"https://secwatch.observer/filing/0001213900-25-014154#claim-24fb6427fb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025014154/0001213900-25-014154-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"f1a5d613da00cbbec03af343cb7e5629d84b6786","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2024-03-20T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2024-03-19","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"InMed Pharmaceuticals Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"March 19, 2024, the\nCompany received written notification (the “Current Notification”) from the Listing Qualifications Department of Nasdaq that\nthe Company has been granted an additional 180-day compliance period, or until September 16, 2024 (the “Extended Compliance\nPeriod”), to regain compliance with the Minimum Bid Price Rule. Nasdaq’s determination is based on the Company meeting\nthe continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on\nthe Nasdaq Capital Market, with the exception of the bid price requirement","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-024305","anchor_url":"https://secwatch.observer/filing/0001213900-24-024305#claim-f1a5d613da00cbbec03af343cb7e5629d84b6786","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024024305/0001213900-24-024305-index.htm"},{"fact_type":"executive_change","fact_key":"1902e4159d","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2024-02-09T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-02-20","interim":false,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":"Netta Jagpal","successor_named":true},"claim":"Jonathan Tegge resigned as Interim Chief Financial Officer at InMed Pharmaceuticals Inc..","evidence_excerpt":"Mr. Tegge will cease, pursuant to the terms of his resignation delivered to the Company on February 8, 2024, to serve as the Company’s Interim Chief Financial Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-011954","anchor_url":"https://secwatch.observer/filing/0001213900-24-011954#claim-1902e4159d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024011954/0001213900-24-011954-index.htm"},{"fact_type":"executive_change","fact_key":"ef2e2521ce","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2024-02-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-02-20","interim":false,"role":"Chief Financial Officer and Corporate Secretary","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Netta Jagpal was appointed as Chief Financial Officer and Corporate Secretary at InMed Pharmaceuticals Inc..","evidence_excerpt":"appointed Ms. N. Netta “Neeta” Jagpal (“ Ms. Jagpal ”) ( aged 51 ) to serve, effective as of February 20, 2024 (the “ Effective Date ”), as Chief Financial Officer and Corporate Secretary of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-011954","anchor_url":"https://secwatch.observer/filing/0001213900-24-011954#claim-ef2e2521ce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024011954/0001213900-24-011954-index.htm"},{"fact_type":"shareholder_vote","fact_key":"409bd55aa6f86d485bf6e1b3e3eb9fd8b17d5c8d","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2023-12-20T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-19","outcome":"passed","proposal_text":"Appointment of Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"123,387","votes_against":"0","votes_for":"1,169,259","votes_withheld":"0"}]},"claim":"InMed Pharmaceuticals Inc. shareholders approved Appointment of Independent Registered Public Accounting Firm at the 2023-12-19 meeting.","evidence_excerpt":"Proposal No. 2—Appointment of Independent Registered Public Accounting Firm The Corporation’s shareholders voted to approve the appointment of Marcum LLP as the independent registered public accounting firm of the Corporation until the 2024 Annual General Meeting of Shareholders or until a successor is named. Votes For % Votes For Vote Against % Votes Against Abstain Broker Non- Votes 1,169,259 90.45% 0 0% 123,387 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-23-097076","anchor_url":"https://secwatch.observer/filing/0001213900-23-097076#claim-409bd55aa6f86d485bf6e1b3e3eb9fd8b17d5c8d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390023097076/0001213900-23-097076-index.htm"},{"fact_type":"shareholder_vote","fact_key":"62ba3cf2037f570193694a7d25030112b566a2c9","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2023-12-20T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-19","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"1,081,422","subject":"Eric A. Adams","votes_abstain":"0","votes_against":"0","votes_for":"160,711","votes_withheld":"50,513"},{"broker_non_votes":"1,081,422","subject":"Andrew Hull","votes_abstain":"0","votes_against":"0","votes_for":"141,398","votes_withheld":"69,826"},{"broker_non_votes":"1,081,422","subject":"Janet Grove","votes_abstain":"0","votes_against":"0","votes_for":"141,882","votes_withheld":"69,342"},{"broker_non_votes":"1,081,422","subject":"Bryan Baldasare","votes_abstain":"0","votes_against":"0","votes_for":"145,659","votes_withheld":"65,565"},{"broker_non_votes":"1,081,422","subject":"Nicole Lemerond","votes_abstain":"0","votes_against":"0","votes_for":"145,865","votes_withheld":"65,359"}]},"claim":"InMed Pharmaceuticals Inc. shareholders approved Election of Directors at the 2023-12-19 meeting.","evidence_excerpt":"Proposal No. 1—Election of Directors The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2024 Annual General Meeting of Shareholders: Nominee Votes For % Votes For Votes Withheld % Votes Withheld Broker Non-Votes Eric A. Adams 160,711 76.09% 50,513 23.91% 1,081,422 Andrew Hull 141,398 66.94% 69,826 33.06% 1,081,422 Janet Grove 141,882 67.17% 69,342 32.83% 1,081,422 Bryan Baldasare 145,659 68.96% 65,565 31.04% 1,081,422 Nicole Lemerond 145,865 69.06% 65,359 30.94% 1,081,422","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-23-097076","anchor_url":"https://secwatch.observer/filing/0001213900-23-097076#claim-62ba3cf2037f570193694a7d25030112b566a2c9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390023097076/0001213900-23-097076-index.htm"},{"fact_type":"material_agreement","fact_key":"1053c18096545b115b1975680a1809b2fd54e0e9","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"two institutional accredited investors","effective_date":null,"item_codes_triggered":["1.01"],"value_text":null},"claim":"InMed Pharmaceuticals Inc. entered into Purchase Agreement with two institutional accredited investors.","evidence_excerpt":"On October 24, InMed Pharmaceuticals Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with two institutional accredited investors (the “Purchasers”), for the sale and issuance of an aggregate of 3,012,049 of its common shares (or pre-funded warrants in lieu thereof) at a purchase price of $0.83 per share (or pre-funded warrant in lieu thereof).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001013762-23-007388","anchor_url":"https://secwatch.observer/filing/0001013762-23-007388#claim-1053c18096545b115b1975680a1809b2fd54e0e9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000101376223007388/0001013762-23-007388-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"e25e6824037c57982f86d325d502c9d8f1465c1a","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2023-09-25T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":"$1.00 per share","notice_date":"2023-09-19","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"InMed Pharmaceuticals Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"September 19, 2023,\nthe Company received written notice from the listing qualifications department staff of The Nasdaq Capital Market (“Nasdaq”)\nnotifying it that the average closing bid price of the Company's common shares over a period of 30 consecutive trading days was below\nthe minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550(a)(2). In accordance with applicable\nNasdaq procedures, the Company has a period of 180 calendar days following the receipt of the written notice mentioned above to cure the\ndeficiency and regain compliance. The no","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-078887","anchor_url":"https://secwatch.observer/filing/0001213900-23-078887#claim-e25e6824037c57982f86d325d502c9d8f1465c1a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390023078887/0001213900-23-078887-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3904bb7b9ae5505660314b48b62a1e34d3a4eb24","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-12-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-15","outcome":"passed","proposal_text":"Appointment of Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"8,047","votes_against":"0","votes_for":"339,548","votes_withheld":null}]},"claim":"InMed Pharmaceuticals Inc. shareholders approved Appointment of Independent Registered Public Accounting Firm at the 2022-12-15 meeting.","evidence_excerpt":"Proposal No. 2—Appointment of Independent Registered Public Accounting Firm The Corporation’s shareholders voted to approve the appointment of Marcum LLP as the independent registered public accounting firm of the Corporation until the 2023 Annual General Meeting of Shareholders or until a successor is named. Votes For % Votes For Vote Against % Votes Against Abstain Broker Non-Votes 339,548 97,68% 0 0% 8,047 0","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-080602","anchor_url":"https://secwatch.observer/filing/0001213900-22-080602#claim-3904bb7b9ae5505660314b48b62a1e34d3a4eb24","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022080602/0001213900-22-080602-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f7fe6e2c49dfa8a9c118c65faaada9f0f77e1d91","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-12-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-15","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"179,813","subject":"Eric A. Adams","votes_abstain":null,"votes_against":null,"votes_for":"159,223","votes_withheld":"8,559"},{"broker_non_votes":"179,813","subject":"Andrew Hull","votes_abstain":null,"votes_against":null,"votes_for":"158,282","votes_withheld":"9,500"},{"broker_non_votes":"179,813","subject":"Janet Grove","votes_abstain":null,"votes_against":null,"votes_for":"162,246","votes_withheld":"5,536"},{"broker_non_votes":"179,813","subject":"Bryan Baldasare","votes_abstain":null,"votes_against":null,"votes_for":"160,764","votes_withheld":"7,018"},{"broker_non_votes":"179,813","subject":"Nicole Lemerond","votes_abstain":null,"votes_against":null,"votes_for":"162,174","votes_withheld":"5,608"}]},"claim":"InMed Pharmaceuticals Inc. shareholders approved Election of Directors at the 2022-12-15 meeting.","evidence_excerpt":"Proposal No. 1—Election of Directors The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2023 Annual General Meeting of Shareholders: Nominee Votes For % Votes For Votes Withheld % Votes Withheld Broker Non-Votes Eric A. Adams 159,223 94.90 % 8,559 5.10 % 179,813 Andrew Hull 158,282 94.34 % 9,500 5.66 % 179,813 Janet Grove 162,246 96.70 % 5,536 3.30 % 179,813 Bryan Baldasare 160,764 95.82 % 7,018 4.18 % 179,813 Nicole Lemerond 162,174 96.66 % 5,608 3.34 % 179,813","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-080602","anchor_url":"https://secwatch.observer/filing/0001213900-22-080602#claim-f7fe6e2c49dfa8a9c118c65faaada9f0f77e1d91","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022080602/0001213900-22-080602-index.htm"},{"fact_type":"executive_change","fact_key":"d35b867f77","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-12-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-12-12","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Jonathan Tegge was appointed as Interim Chief Financial Officer at InMed Pharmaceuticals Inc..","evidence_excerpt":"As described above, the Company appointed Mr. Tegge as Interim Chief Financial Officer of the Company effective December 12, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-079487","anchor_url":"https://secwatch.observer/filing/0001213900-22-079487#claim-d35b867f77","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022079487/0001213900-22-079487-index.htm"},{"fact_type":"auditor_change","fact_key":"8d9b4d3a84db0b7d0c0be131c4ba451904216d92","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-12-13T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Marcum LLP","disagreement_text":null,"effective_date":"2022-12-11","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"InMed Pharmaceuticals Inc. engaged Marcum LLP as its auditor.","evidence_excerpt":"On December 11, 2022, the Audit Committee approved the engagement of Marcum LLP (\"Marcum\") to audit our consolidated financial statements for the fiscal year ending June 30, 2023, subject to Marcum's standard client acceptance procedures.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-079246","anchor_url":"https://secwatch.observer/filing/0001213900-22-079246#claim-8d9b4d3a84db0b7d0c0be131c4ba451904216d92","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022079246/0001213900-22-079246-index.htm"},{"fact_type":"auditor_change","fact_key":"f78e7649f085febfe915e08cae56026a7dc0aaa3","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-12-13T23:59:59+00:00","payload":{"action":"resignation","auditor_name":"KPMG LLP","disagreement_text":null,"effective_date":"2022-12-08","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"KPMG LLP resigned as auditor of InMed Pharmaceuticals Inc..","evidence_excerpt":"On December 8, 2022, KPMG LLP (\"KPMG\"), which had been serving as the independent registered public accounting firm of InMed Pharmaceuticals Inc. (\"we,\" \"us\" or \"our\"), declined to stand for reelection and resigned as our independent registered public accounting firm, effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-079246","anchor_url":"https://secwatch.observer/filing/0001213900-22-079246#claim-f78e7649f085febfe915e08cae56026a7dc0aaa3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022079246/0001213900-22-079246-index.htm"},{"fact_type":"material_agreement","fact_key":"cf3f815cf9e4390335696565f081038eefd7c183","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-11-22T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Engagement Letter","agreement_type":"underwriting","counterparty":"H.C. Wainwright & Co., LLC","effective_date":"2022-09-09","item_codes_triggered":["1.01"],"value_text":null},"claim":"InMed Pharmaceuticals Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2022-09-09).","evidence_excerpt":"The Company entered into an engagement letter with Wainwright, dated September 9, 2022 (the “Engagement Letter”), pursuant to which Wainwright agreed to serve as the Company’s exclusive placement agent, advisor or underwriter in certain offerings, including the Private Placement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-074323","anchor_url":"https://secwatch.observer/filing/0001213900-22-074323#claim-cf3f815cf9e4390335696565f081038eefd7c183","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022074323/0001213900-22-074323-index.htm"},{"fact_type":"material_agreement","fact_key":"83f9dc80454342f88bf2630d636a5dfe39be3e80","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-11-22T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Registration Rights Agreement","agreement_type":"equity_purchase","counterparty":"the Purchasers","effective_date":"2022-11-17","item_codes_triggered":["1.01"],"value_text":null},"claim":"InMed Pharmaceuticals Inc. entered into Registration Rights Agreement with the Purchasers (effective 2022-11-17).","evidence_excerpt":"In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the Purchasers, dated November 17, 2022 (the “Registration Rights Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-074323","anchor_url":"https://secwatch.observer/filing/0001213900-22-074323#claim-83f9dc80454342f88bf2630d636a5dfe39be3e80","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022074323/0001213900-22-074323-index.htm"},{"fact_type":"material_agreement","fact_key":"db5e4f27a111b8c73ffd2922377d21e8cccfabe0","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-11-22T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"two institutional accredited investors","effective_date":"2022-11-17","item_codes_triggered":["1.01"],"value_text":"approximately $6.0 million"},"claim":"InMed Pharmaceuticals Inc. entered into Purchase Agreement with two institutional accredited investors valued at approximately $6.0 million (effective 2022-11-17).","evidence_excerpt":"On November 17, 2022, InMed Pharmaceuticals Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with two institutional accredited investors (the “Purchasers”), for the sale and issuance of an aggregate of 1,818,185 of its common shares (or pre-funded warrants in lieu thereof) at a purchase price of $3.30 per share (or pre-funded warrant in lieu thereof).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-074323","anchor_url":"https://secwatch.observer/filing/0001213900-22-074323#claim-db5e4f27a111b8c73ffd2922377d21e8cccfabe0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022074323/0001213900-22-074323-index.htm"},{"fact_type":"executive_change","fact_key":"6399b2abe7","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-11-17T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Vice President of Accounting and Controller and Principal Accounting Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Sarah Li changed role as Vice President of Accounting and Controller and Principal Accounting Officer at InMed Pharmaceuticals Inc..","evidence_excerpt":"The Company’s Controller, Sarah Li, has been promoted to Vice President of Accounting and Controller and Principal Accounting Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-073492","anchor_url":"https://secwatch.observer/filing/0001213900-22-073492#claim-6399b2abe7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022073492/0001213900-22-073492-index.htm"},{"fact_type":"executive_change","fact_key":"d2cec77639","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-11-17T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2022-11-20","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Brenda Edwards was terminated as Interim Chief Financial Officer at InMed Pharmaceuticals Inc..","evidence_excerpt":"On November 14, 2022, the Company terminated the Consulting Agreement for Brenda Edwards effective November 20, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-073492","anchor_url":"https://secwatch.observer/filing/0001213900-22-073492#claim-d2cec77639","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022073492/0001213900-22-073492-index.htm"},{"fact_type":"executive_change","fact_key":"861c7d33ce","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-08-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-08-08","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Nicole Lemerond was appointed as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"the Board appointed Nicole Lemerond as a director of the Board to fill the vacancy created by Mr. Cutler’s resignation, effective as of August 8, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-046528","anchor_url":"https://secwatch.observer/filing/0001213900-22-046528#claim-861c7d33ce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022046528/0001213900-22-046528-index.htm"},{"fact_type":"executive_change","fact_key":"a582802d26","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-08-11T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-08-08","interim":false,"role":"Director","role_category":"director","successor_name":"Nicole Lemerond","successor_named":true},"claim":"Adam Cutler resigned as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"Adam Cutler resigned from the Board of Directors (the “Board”) (including from the Nominating & Corporate Governance Committee and the Audit Committee) of the Company, effective as of August 8, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-046528","anchor_url":"https://secwatch.observer/filing/0001213900-22-046528#claim-a582802d26","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022046528/0001213900-22-046528-index.htm"},{"fact_type":"executive_change","fact_key":"e7320fcf3b","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-07-20T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-07-15","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Michael Woudenberg was appointed as Chief Operating Officer at InMed Pharmaceuticals Inc..","evidence_excerpt":"On July 18, 2022, InMed Pharmaceuticals Inc. (the “Company”) issued a press release to announce that it has appointed Mr. Michael Woudenberg as the Company’s Chief Operating Officer effective July 15, 2022 (the “Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-040385","anchor_url":"https://secwatch.observer/filing/0001213900-22-040385#claim-e7320fcf3b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022040385/0001213900-22-040385-index.htm"},{"fact_type":"executive_change","fact_key":"aac27b4558","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-05-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-05-12","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Bryan Baldasare was appointed as director at InMed Pharmaceuticals Inc..","evidence_excerpt":"On May 12, 2022, the Board appointed Bryan Baldasare as a director of the Board and concurrently increased the size of the Board to six members, effective as of May 12, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-027887","anchor_url":"https://secwatch.observer/filing/0001213900-22-027887#claim-aac27b4558","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022027887/0001213900-22-027887-index.htm"},{"fact_type":"executive_change","fact_key":"6ba3f16427","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-03-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-04-01","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Brenda Edwards was appointed as Interim Chief Financial Officer at InMed Pharmaceuticals Inc..","evidence_excerpt":"The Company appointed Ms. Brenda Edwards as Interim Chief Financial Officer of the Company effective April 1, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-013457","anchor_url":"https://secwatch.observer/filing/0001213900-22-013457#claim-6ba3f16427","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022013457/0001213900-22-013457-index.htm"},{"fact_type":"executive_change","fact_key":"cfeefb9382","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-03-18T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2022-03-31","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Brenda Edwards","successor_named":true},"claim":"Bruce Colwill retired as Chief Financial Officer at InMed Pharmaceuticals Inc..","evidence_excerpt":"Mr. Bruce Colwill, will be retiring and will be stepping down from his position at the Company effective March 31, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-013457","anchor_url":"https://secwatch.observer/filing/0001213900-22-013457#claim-cfeefb9382","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022013457/0001213900-22-013457-index.htm"},{"fact_type":"executive_change","fact_key":"ea0eeba70a","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-02-23T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-02-11","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Janet Grove was appointed as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"On February 11, 2022, the Board appointed Janet Grove as a director of the Board to fill the vacancy created by Ms. Sazdanoff’s resignation, effective as of February 11, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-008887","anchor_url":"https://secwatch.observer/filing/0001213900-22-008887#claim-ea0eeba70a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022008887/0001213900-22-008887-index.htm"},{"fact_type":"executive_change","fact_key":"1083291172","cik":1728328,"ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-02-23T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-02-11","interim":false,"role":"Director","role_category":"director","successor_name":"Janet Grove","successor_named":true},"claim":"Catherine Sazdanoff resigned as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"On February 11, 2022, Catherine Sazdanoff resigned from the Board of Directors (the “Board”) (including from the Compensation Committee, the Nominating & Governance Committee and the Audit Committee) of InMed Pharmaceuticals Inc. (the “Company”), effective as of February 11,2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-008887","anchor_url":"https://secwatch.observer/filing/0001213900-22-008887#claim-1083291172","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022008887/0001213900-22-008887-index.htm"}]}